Biofrontera Inc BFRI:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 04/26/24 EDT
1.59quote price arrow down-0.10 (-5.92%)
Volume
50,406
52 week range
0.61 - 13.42
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.59
  • 52 Week High13.42
  • 52 Week High Date06/20/23
  • 52 Week Low0.61
  • 52 Week Low Date02/08/24

Key Stats

  • Market Cap8.092M
  • Shares Out5.09M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-42.6

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.59
  • 52 Week High13.42
  • 52 Week High Date06/20/23
  • 52 Week Low0.61
  • 52 Week Low Date02/08/24
  • Market Cap8.092M
  • Shares Out5.09M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-42.6

RATIOS/PROFITABILITY

  • EPS (TTM)-15.19
  • P/E (TTM)-0.10
  • Fwd P/E (NTM)-0.47
  • EBITDA (TTM)-20.87M
  • ROE (TTM)-140.43%
  • Revenue (TTM)34.073M
  • Gross Margin (TTM)48.80%
  • Net Margin (TTM)-59.08%
  • Debt To Equity (MRQ)81.45%

EVENTS

  • Earnings Date05/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Biofrontera Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription...
Hermann Luebbert Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Eugene Frederick Leffler III
Chief Financial Officer
Address
120 Presidential Way,, Suite 330
Woburn, MA
01801
United States